Overview
Testosterone is a normal female hormone — women produce more of it by quantity than estrogen, and it declines gradually with age rather than dropping at menopause.
But the honest answer to "should women take testosterone" is narrower than the market implies, and it is worth stating precisely.
The international consensus position, agreed across the major menopause and endocrine societies, supports one evidence-based indication: hypoactive sexual desire disorder in postmenopausal women — distressing low sexual desire, after other contributing causes have been addressed. For everything else, the evidence is insufficient to recommend it.
| Claimed use | What the evidence supports |
|---|---|
| Low sexual desire, postmenopausal, distressing | Supported. The one indication with consensus behind it |
| Energy and fatigue | Insufficient evidence |
| Mood and wellbeing | Insufficient evidence |
| Cognition | Insufficient evidence |
| Muscle and strength | Insufficient evidence at female physiological doses |
| Bone density | Insufficient evidence as an indication on its own |
| Premenopausal women | No indication. Evidence does not support it |
| Treating a "low" blood level | There is no level that defines deficiency in women |
The most important line here: there is no blood testosterone level that diagnoses deficiency in a woman or predicts who will respond to treatment. Testing is used to exclude high levels and to monitor treatment — not to establish a need for it. Any offer that starts with "your testosterone is low for your age" is not following the evidence.
Why there is no diagnostic threshold
Three reasons, and together they are decisive.
Assay accuracy. Standard immunoassays were designed for male ranges and perform poorly at the much lower concentrations found in women. The results are unreliable at exactly the levels being interpreted.
No correlation with symptoms. Studies have not found a consistent relationship between a woman's testosterone level and her sexual function. Women with levels at the bottom of the range are frequently fine; women in the middle are frequently not.
No predictive value. Level does not predict who responds to treatment, which is what a useful diagnostic test would need to do.
So the consensus position is that treatment is considered on the clinical picture — distressing low desire, other causes addressed — rather than on a number. Testing has a role in checking a level is not already high before starting, and in monitoring that it stays within the female physiological range during treatment.
This distinction is where most of the commercial activity in this space diverges from the evidence. How the same problem plays out with ranges generally.
What "after other causes have been addressed" means
The qualifier is doing a lot of work and it is where most women should actually start.
Pain or dryness with sex. The most common and most treatable cause of low desire in midlife women, and frequently the whole answer. Should be addressed before testosterone is considered. What local treatment does.
Estrogen status. Testosterone in women is generally given alongside adequate estrogen rather than instead of it.
Medication. SSRIs, SNRIs and several others reduce desire, and there are usually options.
Mood, sleep, fatigue and relationship context. All affect desire directly, and none respond to testosterone.
Thyroid, iron and prolactin, each of which reduces libido and each of which is straightforward to check.
The full list, in the order it usually matters.
Working through that list resolves the problem for a substantial share of women without any testosterone at all. Skipping it is how a treatment with one narrow indication gets sold to everyone.
What is realistic where it is indicated
Where it is appropriate, the effect is real but modest — trials show a statistically significant improvement in desire and in satisfying sexual events, of a size that matters to some women and not to others. It is worth knowing that going in, because the marketing implies something more dramatic.
Two practical points that shape the treatment.
There is no approved female testosterone product in most markets, including the United States. Treatment generally means using a male product at a fraction of the male amount, or a compounded preparation — which is why it must be prescribed and monitored by someone who does this regularly, and why self-directed use is genuinely risky.
Monitoring is not optional. Levels are checked to confirm they remain within the female physiological range, because exceeding it is where the side effects come from — acne, unwanted hair growth, and with sustained excess, voice deepening and clitoral enlargement, which may not fully reverse. Those are the reasons the consensus statement is specific about physiological dosing and monitoring.
A trial period is usual, with a decision at around six months about whether it is doing anything.
Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product.
Why we are cautious
Testosterone for women is one of the fastest-growing offerings in this market, and it is frequently sold on reasoning the evidence does not support: that a level in the lower range constitutes deficiency, that it treats fatigue and brain fog, and that it is a general vitality treatment.
None of that is established. Meanwhile the one indication with consensus behind it — distressing low desire, postmenopausal, other causes addressed — is a real indication that we take seriously and treat where appropriate.
Being honest about the difference is not caution for its own sake. It is what prevents a woman being treated for a year for the wrong thing while the actual cause goes unaddressed.
Frequently asked questions
Should women take testosterone? There is one evidence-supported indication: distressing low sexual desire in postmenopausal women, after other causes have been addressed. Other uses are not supported by current evidence.
Can a blood test tell me if mine is low? No level defines deficiency in women or predicts response. Testing is used to exclude high levels and to monitor treatment, not to establish a need for it.
Will it help my energy or brain fog? The evidence is insufficient to support those uses. Fatigue and cognitive symptoms in midlife usually have other explanations that are worth finding.
Is it safe? Within the female physiological range and with monitoring, side effects are generally mild and reversible. Excess causes acne and unwanted hair growth, and sustained excess can cause changes that do not fully reverse — which is why monitoring matters.
What about before menopause? The evidence does not support an indication in premenopausal women.
Where this fits in your plan
If low desire is what brought you here, the productive sequence is to work through the more common and more treatable causes first — discomfort, medication, sleep, mood, thyroid and iron — because for many women the answer is in that list.
Where it is not, testosterone within its actual indication is a real option, prescribed at physiological levels and monitored properly. What we offer and how it works.
We measure first. Then we act.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
